TRAWS PHARMA ($TRAW) posted quarterly earnings results on Monday, March 31st. The company reported earnings of $95.66 per share, beating estimates of -$9.74 by $105. ...
*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces the ...
Traws Pharma Inc. (NASDAQ: TRAW) on Wednesday shared interim data from an ongoing randomized, open-label Phase 2 with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor.
Traws Pharma (NASDAQ:TRAW) stock plunged 43% Monday after the drug developer announced a nearly $73M financing to support development of its H5N1 bird flu drug candidate Tivoxavir Marboxil. The ...
Traws Pharma, Inc. (NASDAQ:TRAW) shares are rocketing on Monday after the company disclosed advancements in the development of its one-dose investigational treatment for H5N1 bird flu, tivoxavir ...
Hosted on MSN
Traws Pharma reports positive phase 2 trial results
An announcement from Traws Pharma ( (TRAW)) is now available. Traws Pharma announced positive interim results from a Phase 2 trial of ratutrelvir, a ritonavir-free oral COVID-19 treatment, on December ...
Traws Pharma (TRAW) has delivered a -52.980% change over the past year, with a 52-week range between 0.970 and 3.750. What Is the Average Daily Trading Volume of Traws Pharma (TRAW)? The average daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results